Burzynski Research Institute Presents Positive Results From Phase II Trials of ANP for Inoperable Brainstem Glioma at the Congress

Published: May 11, 2009

HOUSTON--(BUSINESS WIRE)--The Burzynski Research Institute, Inc. (BRI) announced today that it made three presentations of the results of phase II trials and mechanism of action data on it’s antineoplaston A10 and antineoplaston AS2-1 therapy (ANP). These findings were discussed at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology in Yokohama, Japan.

Back to news